Clinical Trials Directory

Trials / Completed

CompletedNCT02014662

A Methodology Study to Assess Muscle Damage After Eccentric Exercise

A Pilot Study to Measure Force Recovery and Protein Synthetic Rates After Unilateral Eccentric Exercise in Healthy Males Volunteers Unaccustomed to Eccentric Exercise

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
Male
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

An isolated bout of unaccustomed maximal eccentric exercise is associated with muscle force loss for 2-4 days, mild reversible muscle tenderness, and ultra-structural damage to the muscle fibers, elevation of muscle proteins in serum, and a detriment in range of motion. This single center, pilot study is designed to optimize conditions for the robust measurement of functional deficits after muscle damage and to identify markers of repair over 22 days to inform future intervention studies. The primary measure will be limb force (assessed electronically from the ergometer), previous studies have demonstrated that functional measures return fairly rapidly, usually between 2-4 days. Additionally, several biomarkers of muscle function will be measured over 22 days, as well as changes in protein synthesis in biopsy samples Deuterium-labelled water (D2O) will be consumed by all study participants from Day-3 through Day 22 to aid in quantifying newly synthesized proteins.

Conditions

Interventions

TypeNameDescription
OTHEREccentric exerciseEach subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.

Timeline

Start date
2014-01-14
Primary completion
2014-07-02
Completion
2014-07-02
First posted
2013-12-18
Last updated
2017-05-15

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02014662. Inclusion in this directory is not an endorsement.